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ABSTRACT: Carbon nanomaterials, including 2D graphene-
based materials, have shown promising applicability to drug
delivery, tissue engineering, diagnostics, and various other
biomedical areas. However, to exploit the benefits of these
materials in some of the areas mentioned, it is necessary to
understand their possible toxicological implications and long-
term fate in vivo. We previously demonstrated that following
intravenous administration, 2D graphene oxide (GO) nano-
sheets were largely excreted via the kidneys; however, a small
but significant portion of the material was sequestered in the
spleen. Herein, we interrogate the potential consequences of
this accumulation and the fate of the spleen-residing GO over a
period of nine months. We show that our thoroughly characterized GO materials are not associated with any detectable
pathological consequences in the spleen. Using confocal Raman mapping of tissue sections, we determine the sub-organ
biodistribution of GO at various time points after administration. The cells largely responsible for taking up the material are
confirmed using immunohistochemistry coupled with Raman spectroscopy, and transmission electron microscopy (TEM).
This combination of techniques identified cells of the splenic marginal zone as the main site of GO bioaccumulation. In
addition, through analyses using both bright-field TEM coupled with electron diffraction and Raman spectroscopy, we reveal
direct evidence of in vivo intracellular biodegradation of GO sheets with ultrastructural precision. This work offers critical
information about biological processing and degradation of thin GO sheets by normal mammalian tissue, indicating that
further development and exploitation of GO in biomedicine would be possible.
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Graphene-based materials (GBMs) have potential forexciting applications including those related to medicaltechnologies, such as improved drug delivery.1−4 A key
concern, however, is the implications of interactions of these
engineered nanomaterials with the mammalian biological
milieu.5 Understanding the fate of GBMs after administration
to the body and the materials’ tendencies to accumulate within
organs and cells, especially those of the mononuclear phagocytic
system (MPS), such as the lungs, liver and spleen, and the effects
thereof,6,7 are key in defining whether GBMs will be suitable for
biomedical applications.
Preferential accumulation of nanomaterials in one component
of the MPS over another is typically influenced by the route of
administration and the physicochemical characteristics of the
materials administered.8 We and others have reported the
accumulation of functionalized GBMs in the spleen following
intravenous (i.v.)6,9 and intraperitoneal administration.7 Splenic
accumulation after i.v. administration is not restrictive only to
GBMs;6 it has been reported for various other nanomateri-
als.10,11 In terms of physicochemical characteristics, we showed
that thicker GBMs such as multilayer graphene oxide (GO)
sheets are more likely to be trapped within the capillary beds of
the lungs compared with single-to-few-layer GO sheets, after
systemic administration.12 Single-to-few-layer GO sheets, on the
other hand, have a greater capacity to be excreted via the urinary
tract and for the small fraction of this material that remained in
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the body, this was shown to accumulate predominantly within
the spleen.9,12
The spleen is a highly specialized organ; it forms a major part
of the MPS and has major functions in the innate and adaptive
branches of the immune system.13 It is adapted to filtering blood
via the strategic placement of an array of phagocytic cells, such as
specialized macrophages. These phagocytic cells act to “clean”
the blood of foreign-body invaders and particulates. The filtered
blood is then returned to the main circulation via the efferent
splenic vein.13 The spleen also contains large numbers of
lymphoid cells and antigen-presenting cells, such as dendritic
cells. If foreign-body invaders or particulates, such as GBMs, are
recognized by these cells as antigens, they may induce antigen-
specific immune responses.14,15 Besides immune-related func-
tions, the spleen also plays an important role in the maintenance
of a healthy red blood cell (RBC) population and the storage of
iron.13
Accumulation of GBMs within the spleen following
administration has been reported to be without toxicological
consequences.7 At the same time, however, various reports have
detailed extensive immune responses characterized by upregu-
lation of inflammatory markers as well as histopathological
changes6 following the administration of GBMs. Such
discrepancies are often linked to the inhomogeneity in
physicochemical properties, such as thickness, lateral dimen-
sions, and levels of surface functionalization, of the administered
GBMs between investigations.8,16 Thick, large, or poorly
functionalized sheets are more likely to have detrimental
consequences compared with thin, small, well-functionalized,
and highly dispersed materials. Variations in GBM character-
istics can, therefore, determine the impact of the materials on
biological systems8 and consequently affect its applicability in
biomedical research particularly with regard to systemic drug
delivery.
GO sheets are a promising class of GBMs that have been
investigated extensively in biomedicine; like other GBMs, they
are often complex and poorly characterized, leading to
discrepancies in the literature in terms of toxicology. One
aspect that is particularly sensitive to variations in physicochem-
ical characteristics is the in vivo long-term fate and, in particular,
the biodegradability of the materials.5,17,18
The degradability of GO, as well as related carbon
nanomaterials, has been reported in the literature under different
conditions mimicking biological processes. Various studies
describe degradative processes mediated by oxidizing chem-
icals,19−22 as well as free radicals (reactive oxygen species or
reactive nitrogen species) generating enzymes, including some
that are relevant to mammals.17,18,23−26 Such studies have
suggested that the colloidal characteristics of GO dispersions,
and the material characteristics that control these, are important
determinants of the biodegradability of the materials.17 Low
levels of surface functionalization and increased thickness are,
for instance, likely to promote poor dispersibility and
aggregation/agglomeration of the materials, thereby hindering
their enzyme-mediated biodegradation; the contrary would
promote it.17,18 However, these studies provide limited
information as to the potential of GBMs to degrade in vivo.
In this respect, the most advanced study so far describes the
biodegradability of carboxylated graphene (GO-like materials)
over a period of three months in mice, using confocal Raman
spectroscopy.6 The authors reported the continuing but
incomplete biodegradation of thick graphene-based aggregates
in different organs of the MPS with ensuing development of
associated pathological features.6 Noticeably, the spleen was
shown to degrade the accumulated material at a faster rate
compared with other components of the MPS.6
In order to develop GO as a potential vehicle for therapeutics
or diagnostics, more work is required to determine the exact
degree of biodegradability of these materials in vivo. In previous
reports, we demonstrated that after i.v. administration, single-to-
few-layer GO sheets are largely excreted via the kidneys and
urinary tract.9,27 We quantified the amount of material excreted
as well as that retained in the body and examined the interaction
of GO with the kidneys and its toxicological consequences.27
Importantly, we showed that a small, yet significant, proportion
of this thin material was sequestered within the spleen. Herein,
Figure 1. Physicochemical characterization of GO, prior to injection. (a) AFM image, with corresponding graphs showing the distribution of
sheet thickness and lateral dimensions. (b) TEM. (c) Raman spectroscopy with I(D)/I(G) ratio. (d) Electron diffraction pattern with the
corresponding SAED aperture micrograph given in Figure S1. Further physicochemical characterization is shown in Figure S2.
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we build on these previous findings and report a much-needed
long-term study investigating both the impact and in vivo
biodegradability of the portion of the small and thin GO sheets
sequestered within the spleen over nine months following i.v.
administration in mice.
RESULTS AND DISCUSSION
Two criteria are preferable in the development of engineered
nanomaterials for biomedical applications: a safe in vivo profile
in the context of the designated application and the capacity for
effective, or controlled, biodegradation or body elimination.5
Among GBMs, GO sheets are the most studied oxidized
derivatives of sp2-hybridized carbon nanomaterials for bio-
medical applications. This is due to their relatively hydrophilic
nature and amenability to surface functionalization.28 These
features give GO sheets a strong capacity particularly regarding
the design of two-dimensional nanoscale carriers for drugs and
other pharmaceutical agents.2,29,30 However, information
concerning the in vivo safety profile and fate over time of GO
sheets is limited.5 Considering our previous study, which
demonstrated that the spleen is the primary organ of
accumulation of the GO dose fraction not excreted via the
Figure 2. Effect of GO on spleen structure. H & E-stained spleen sections (5 μm thick) are shown after injection of GO (2.5, 5, and 10 mg/kg),
Dex 5% (negative control), and LPS 5mg/kg (positive control) after (a) 24 h and (b) onemonth postinjection. The first column is composed of
20× magnification images. Scale bars represent 100 μm. The middle and last columns show 60× magnifications of red and white pulps,
respectively. The scale bars represent 50 μm. The inset images show 300× magnified regions with scale bars that represent 5 μm. (c)
Quantification of the total cells with brown pigmentation detected in spleen sections. Data are represented as mean ± standard error (SE).
Statistical significance was assessed via the Kruskal−Wallis multiple comparison test and Dunns’ posthoc test (*p < 0.05, ***p < 0.005 vs age-
matched negative control). There were n = 3−4 mice per group.
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kidney after i.v. administration in mice,9 the primary objective of
the present study was to understand the impact of this
accumulation on the spleen structure and function and to reveal
the in vivo fate (i.e., biodegradability) of the GO sequestered
within the spleen.
BIOLOGICAL-GRADE GO SHEETS HAVE IDEAL
FEATURES FOR BIOMEDICAL STUDIES
Various reports have detailed the importance of properly
defining and characterizing GBMs in biomedical research.5,16,31
Characteristics such as lateral dimensions, thickness, and surface
functionalization are key determinants of the impact of GBMs
on biological systems.8 Following the production of an aqueous
GO suspension, an extensive physicochemical characterization
of the GO sheets was performed. First, atomic force microscopy
(AFM) and transmission electron microscopy (TEM) were
used to confirm the synthesis of single-to-few-layer GO sheets
with lateral dimensions below 2 μm with a log-normal
distribution (Figure 1A and B). Previous studies recommend
that when injecting colloidal particles intravenously, the material
dimensions should not exceed the diameter of a capillary (5−7
μm).32 This is because the materials must be able to journey
through these narrow blood vessels following administration
without getting trapped, for example, in the lung capillary
bed.8,32,33
Spectroscopic analysis was then performed and consistent
with that expected of GO: an sp2-hybridized carbon hexagonal
lattice interspersed with oxygen functionalities. Raman spec-
troscopy showed enhanced scattering in the D band relative to
the G band (Figure 1C), which indicated the presence of defects
within the graphitic backbone of GO. This finding was
corroborated by the hexagonal electron-diffraction pattern,
which showed diffusivity within the diffraction rings, suggestive
of the presence of crystalline and noncrystalline regions within
the GO sheets (Figure 1D). The corresponding electron
micrograph is provided in Figure S1. Attenuated total
reflectance Fourier-transform infrared spectroscopy (ATR FT-
IR) indicated that these defective regions were occupied by
various oxygen-containing functional groups (Figure S2A). For
instance, stretching vibrations of the O−H bond were observed
as a broad band between 3000 and 3700 cm−1;34 these likely
originated from hydroxyl and carboxyl groups and residual
tightly bound water molecules. Aliphatic C−H stretching
vibrations were observed as a minor band around 2815
cm−1,35 while stretching vibrations originating potentially from
CO groups, present in carbonyl and carboxyl groups, were
demonstrated by a sharp peak at approximately 1725 cm−1.28,34
Evidence of in-plane vibrations in cyclic aromatic networks were
also observed as very weak bands between 1500 and 1600
cm−1,28,36 although, O−H bending modes in adsorbed water
molecules, expected around 1625 cm−1, may have also
contributed.28,37 Bending vibrations of O−H present in
hydroxyls were detectable as a strong band around 1400
cm−1.28,37 Evidence of ether groups could also be detected; they
have previously been reported to result in intense absorption
bands around 1045 and 965 cm−1, which correspond to C−O
stretching vibrations;28,34 epoxides may finally have contributed
to vibrations around 850 cm−1.28 These inferences were
supported by thermogravimetric analysis (TGA) (Figure S2B)
and X-ray photoelectron spectroscopy (XPS) (Figure S2C-i and
C-ii) data. TGA data also indicated that these defected regions,
occupied by oxygen-containing functionalities, constituted
about 40% w/w of total GO. Ultraviolet−visible (UV−vis)
(Figure S2D) and fluorescence (Figure S2E) spectroscopies
further revealed characteristic absorption and fluorescence
curves expected for GO.
Polar oxygen-containing functionalities, as detected on our
GO material, are known to minimize the thermodynamic
consequences of hosting hydrophobic carbon-based materials in
the hydrogen-bonding network of aqueous environments.38 In
our case, this allowed the formulation of a well-dispersed GO
aqueous preparation. Overall, the characterization results
demonstrate the successful preparation of colloidal dispersions
of GO nanosheets suitable for i.v. administration.8,33 Based on
the literature and our previous work, small, well-dispersed, and
thin GO sheets are less likely to cause adverse reactions due to
physical entrapment in capillaries and other small blood
vessels.12 Small, well-dispersed sheets are also more likely to
be excreted via the kidneys and urinary tract,12 and regarding the
small portion of material that remains within the body, these
have a greater chance of interacting with cells without causing
damage.39
GO SHEETS HAVE LIMITED EFFECT ON SPLEEN
HISTOPATHOLOGY
Following characterization and confirmation that the GO sheets
were of small lateral dimensions, single-to-few layers, and
extensively surface oxidized, dispersed material was adminis-
trated to mice via i.v. injection. Based on the material
physicochemical features, the GO sheets were expected to
accumulate over time in the spleen, as previously reported by us9
and others7,40 independently. However, we could not find any
study that examined the consequences of GO accumulation on
the splenic structure or function at the administered doses used
here (2.5, 5, or 10 mg/kg).9,27
This prompted us to explore the possible effects of the
accumulated material, first on spleen histology. Using H & E
staining, we observed no histopathological changes or tissue
damages at either 24 h (Figure 2A) or one month (Figure 2B)
after GO administration at doses of 2.5, 5, or 10 mg/kg.
Magnified regions of both red and white pulps were
histologically normal in GO-injected mice and showed no
apparent difference compared with those of mice injected with
the vehicle control, namely, dextrose 5% (Dex 5%, negative
control). In contrast, mice injected with bacterial lipopolysac-
charide 5 mg/kg (LPS, positive control; used widely to study
acute toxicological responses)41 exhibited a reduction in the
extent of hematoxylin staining, especially in the red pulp, which
is indicative of cell death. These findings were consistent with
other reports,7 although some have demonstrated GO-induced
structural changes associated with significant pathological
implications.42 Differences in observations between studies are
thought to be due to differences in the physicochemical
characteristics of the GBMs used, particularly thickness, lateral
dimensions, and dispersibility.8
In addition to a normal histological appearance of the spleen,
we observed that with increasing doses of GO (2.5, 5, or 10 mg/
kg), there was an increase in the number of individual cells
showing brown pigmentation in comparison to the controls
(insets in Figure 2A (24 h) and 2B (1 month)). All cells that
visually appeared brown were counted (Figure 2C), with no
specific exclusion criteria applied to reduce bias. At 24 h after
GO administration, increase in pigmentation was particularly
apparent in the red pulp andmarginal zone regions of the spleen.
This increase in pigmentation in GO-treated animals compared
with controls was more pronounced at one month, compared
ACS Nano www.acsnano.org Article
https://dx.doi.org/10.1021/acsnano.0c03438
ACS Nano 2020, 14, 10168−10186
10171
Figure 3. Effect of GO on spleen function, after 24 h and one month postinjection of GO at different concentrations (2.5, 5, 10 mg/mL)
compared with control mice, Dex 5% (negative control), and LPS 5 mg/kg-injected (positive control) mice. (a) Blood smears stained with H&
E at two magnifications, 60× (scale bar 50 μm) and inset images 300× (scale bar 5 μm). The graph represents the percentage of deviant RBCs
(reticulocytes, abnormal and aged RBCs) from the total RBC counts; the black arrows indicate some of the deviant RBCs detected in LPS-
injected mice. The graph was obtained after counting >500 cells from each mouse (n = 3 per group). (b) Pearls’ Persian blue-stained spleen
tissue sections (5 μm thick) at two magnifications, 20× (scale bar, 100 μm) and inset images 100× (scale bar, 20 μm). Blue spots demonstrate
regions of Persian blue-stained hemosiderin. The graph represents the percentage of total imaged tissue that stained blue, indicating the
presence of hemosiderin. This was obtained bymeasuring the intensity of the blue-stained regions from 3 or 4 images from eachmouse captured
at 20× (n = 3, 4 mice per group) by Fuji Image J analysis. (c) Spleen T-lymphocyte cell counts, CD4+ T-helper cell counts plot (left), and
cytotoxic CD8+ cell count plot (right). Cell counting was performed by flow cytometry. Three repeat counts were performed for each group of
mice (n = 3). (d) Gene expression levels of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α and gene expression levels of anti-inflammatory
cytokines IL-10 and TGF-β. (a) and (b) represent the spleen hematological function, while (c) and (d) represent the spleen immunological
functions. In (a), (b), and (c) data are represented as mean± standard error (SE), while for the RT-q-PCR in (d), data are represented as mean
± standard deviation (SD). Statistical significance was performed by using the Kruskal−Wallis multiple comparison test and Dunn’s posthoc
test, while the Welch ANOVA and Games−Howell’s posthoc test was used in D. In all cases statistics are *p < 0.05, **p < 0.01, ***p < 0.005 vs
negative control.
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with 24 h. At one month, the presence of brown-pigmented cells
was also evident in the white pulp at the maximum dose (10mg/
kg). In our previous study, a similar appearance of dark brown/
black pigmented cells was noted in the red pulp of spleens of
mice injected with functionalized GO sheets ( fGO).9 Other
studies have also reported dark local regions in theH&E stained
tissue sections of organs (including lungs and liver) following
administration of GO or fGO.43−45 The dark local regions in
these studies were attributed to accumulation of foreign carbon
nanostructures.46 However, at this level of information, dark or
brown regions could be indicative of substances other than GO,
such as iron, which is known to be stored in the spleen as
hemosiderin, preferentially in the red pulp.47,48 In addition to
the microarchitecture, the general appearance of the whole
spleen was examined (Figure S3). During the early stages, i.e., 24
h after injection, there was a notable darkening of the spleens
particularly following the injection of the highest GO doses.
Wen et al. demonstrated a similar dark black coloration of the
whole spleen in mice injected with fGO. This darkening also
increased when the administrated dose (up to 16 mg/kg)
increased.49
To further assess the possible impact of GO i.v. injection at the
tissue level, terminal deoxynucleotidyl transferase (TdT) dUTP
nick-end labeling (TUNEL) staining was performed on spleen
sections (Figures S4 and S5). While the LPS-positive control
was clearly inducing a higher number of TUNEL-positive cells
compared with the negative control, GO was consistently
inducing a higher number of TUNEL-positive apoptotic cells
(about twice the amount found in negative control) for both
time points tested, only at the highest tested dose (i.e., 10 mg/
kg). Although the total number of TUNEL-positive apoptotic
cells in GO groups was still within the norms expected for the
spleen,50,51 but significantly lower than in the LPS control, these
findings were suggestive that 10 mg/kg could likely be the
lowest-observed-adverse-effect level (LOAEL) for the tested
material in this animal model.
GO SHEETS HAVE LIMITED EFFECTS ON SPLENIC
FUNCTION
In order to further study the effect of GO on the spleen and
clarify the possible risk associated with the 10 mg/kg dose, the
two main splenic functions, namely, hematological and
immunological, were interrogated. The hematological function
concerns primarily the ability of the red pulp macrophages to
eliminate aberrant and old RBCs.52−56 Figure 3A presents
optical microscopy images of H & E-stained blood smears of
mice injected with GO at doses of 2.5, 5, or 10 mg/kg, at 24 h
and one month compared with those of mice injected with Dex
5% (negative control) or 5 mg/kg LPS (positive control). Black
arrows indicate deviant RBCs in a representative LPS-injected
mouse blood smear. Quantification of the deviant RBCs is
provided as bar chart in the same figure. Aberrant RBCs
normally do not account for more than 3% of total RBCs.57 The
graph, therefore, presents evidence of normal levels of aberrant
RBCs (about 3%)57 for all groups injected with GO, regardless
of the concentrations, at both 24 h and one month after
administration. The LPS-injected group (positive control),
however, exhibited elevated levels of abnormal RBCs (7%)
relative to the negative control (Dex 5%) and significantly above
the physiological level (3%).57 This was expected, as LPS
administration has been shown to result in increased RBC
deformation.41
The other aspect of hematological function58 of the spleen is
its capacity to serve as a reservoir for biologically important
metals, such as iron in the form of hemosiderin in red pulp
macrophages.59−61 Figure 3B presents Perls’ Prussian blue
staining that was used to detect the hemosiderin content
(stained in blue; quantification presented in bar chart) in mouse
spleen sections at 24 h and one month after injection with
different concentrations of GO (2.5, 5, or 10 mg/kg). As
expected, the levels of hemosiderin increased with the age of the
mice (as seen in Dex 5%-treated animals between the 24 h and
30 day time points). As also expected, there was a significant
reduction in the amount of hemosiderin in LPS-treated mice;
this can be attributed to the marked cell death known to be
induced by LPS.62 At 24 h and one month, neither a decrease
nor increase in hemosiderin was observed in GO-treated mice,
regardless of dose, when compared with age-matched Dex 5%-
treated mice.
Taken together, these results indicated that the spleen was
able tomaintain both a healthy RBC population (Figure 3A) and
its iron-storage capability (Figure 3B) after GO administration
irrespective of the dose used. Other studies have reported a
similar absence of changes in the overall spleen hematological
parameters of mice injected with a single dose of GBMs of up to
10 mg/kg after 48 h43 and 10 days,63 or even with doses as high
as 60 mg/kg after 24 h.64 The same finding is true after repeated
administration of 10 mg/kg every 2 days for up to 22 days,65 15
mg/kg every other day for 14 days,66 or even after repeated oral
administration of high doses of GO (60 mg/kg) every 24 h for
five consecutive days.67
In addition to providing information about the hematological
function of the spleen, the Perls’ Prussian blue staining provided
additional information concerning the identity of the brown-
pigmented features, previously observed in the splenic marginal
zones of GO-treated mice (Figure 2). Most of the brown
material in the red pulp was stained blue and, therefore, was
confirmed to be hemosiderin. In contrast, in cells of the splenic
marginal zone, or their close vicinity, brown material (unstained
by the Perls’ Prussian blue dye) continued to be observed in
spleen sections of GO-treated mice, compared with control
groups. This further confirmed that the brown-pigmented
material present in the marginal zones of GO-treated mice was
not hemosiderin but more likely GO.
We then investigated the immunological function of the
spleen (Figure 3C and D). Emphasis was put on cell-mediated
immunity, which was measured by determining the populations
of T lymphocytes, specifically CD4+ and CD8+ cells as the major
immune component of the splenic white pulp.68,69 Cell-
mediated immunity has a crucial role in the recognition and
elimination of antigenic substances such as abnormal cells and
foreign matter.15 Cell counts for both T helper CD4+ and T
cytotoxic CD8+ cells are presented in Figure 3C (representative
flow cytometry plots outlining CD4+ and CD8+ populations are
provided in Figure S6). The graph shows that there were
moderate changes in CD4+ and CD8+ cell populations in mice
injected with GO (2.5, 5, and 10 mg/kg) at both 24 h and one
month after administration when compared with the age-
matched negative controls (Dex 5%). In contrast, LPS-injected
mice showed a significant reduction in both cell populations
(Figure 3C). These data were in agreement with the findings of
Wang et al., who showed no changes in CD4+ and CD8+ T-cell
populations in spleens of mice injected with two different types
of graphene nanosheets at 1 mg/kg after i.v. injection.45
Interestingly, the same study demonstrated that there was a
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significant rise in both CD4+ and CD8+ T cells after
administration of multiwalled carbon nanotubes (CNTs) at
the same dose and that this rise persisted for more than 7 days.45
Such results illustrate how different types of carbon nanoma-
terials (GBMs or CNTs) may interact with biological systems in
Figure 4. Localization and abundance of GO in spleen tissue at different time points following the administration of 7.5mg/kgGO. (a) Confocal
Raman correlation maps of GO Raman signatures detected in mice spleen sections at different time points (day 1, 30, and 270) post-GO
administration. The horizontal length scale bar represents 200 μm.The vertical heat scale bar (black−white) indicates 40−80% correlation with
spectra of starting material shown in Figure 1c. (b) Overlay image of the immunostaining of MZM (green) and nuclei (blue) with bright field
images, together with correlative Raman spectra of regions of interest, at different time points (day 1, 30, and 270). The white circles and their
corresponding numerical identities indicate different regions of interest where the Raman spectra were acquired. The corresponding numbered
spectra are inset in the respective images. Scale bars represent 50 μm. (c) The percentage of cell-sortedMZMs that screened Raman positive for
GO over time (n = 20 spectra for each of three animals at each time point). (d) Apoptotic cell density detected as per the TUNEL assay, for GO
and Dex 5% treated groups at different time points (day 1, 30, and 270). Statistical significances were tested using the Kruskal−Wallis multiple
comparison test with Dunn’s posthoc test. A full breakdown of the results of the statistical analysis for graphs C and D is provided in Tables S1
and S2, respectively. In all cases, statistical significance was defined where p < 0.05.
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different ways and, thereby, result in different biological
outcomes.5
To expand our study on the immunological function of the
spleen, we analyzed the gene expression profiles of various
cytokines, including pro-inflammatory (IL-6, IL-1β, and TNF-
α) and anti-inflammatory (IL-10 andTGF- β)mediators. Rise in
cytokine expression is typical evidence of CD4+ T-cell activation
and is known to mediate CD8+ cells’ and B-cells’ functions.14
Herein, no significant differences in the levels of the pro-
inflammatory cytokines IL-6 and TNF-α were detected at any
time point in mice injected with GO (2.5, 5, or 10 mg/kg)
compared with mice injected with Dex 5% (Figure 3D). This
was in agreement with the findings of Wang et al., who also did
not detect any change in cytokine levels following the i.v.
injection of graphene nanosheets, even 1 week after admin-
istration.45 There was, however, a significant increase at 24 h in
IL-1β expression for all GO-injected mice (Figure 3D); this
increase was also noted by Orecchioni et al. at 24 h after the
incubation of GOwith human immune cells.70 After one month,
IL-1β levels returned to normal in mice treated with the lowest
concentrations of GO (2.5 and 5 mg/kg), indicating that this
effect was transient and due to a mild inflammatory response
occurring soon after injection. However, at 10 mg/kg and in
contrast to the 2.5 and 5 mg/kg doses, IL-1β levels were
significantly reduced at the one-month time point. Noticeably,
there was also a significant reduction in anti-inflammatory
cytokine expression at 24 h, in particular IL-10 in mice injected
with 2.5, 5, and 10 mg/kg of GO, and TGF-β in mice injected
with 10mg/kg of GO. Levels of both IL-10 and TGF-βwere also
significantly reduced at the one-month time point for all tested
GO doses.
Such cytokine suppressive effects of GO have been previously
reported by Sydlic et al. following the administration of GO at 20
mg/kg.71 The authors attributed such effects to a protective
mechanism associated with the adverse effects of GO.71
Suppression of cytokine expression could also be due to direct
inhibitory effects of GO on secreting cells (e.g., primarily
macrophages in the case of TGF-β72 or monocytes and
macrophages in case of both IL-1073 and IL-1β74) by a
mechanism that does not involve secondary regulatory effects75
or decreased responsiveness of such cells.76 T cells are the main
source of IL-6,77 while TNF-α is primarily secreted by
macrophages but can also be produced by other cells, such as
CD4+ T cells. T-cell populations were, however, unaltered in the
present study (Figure 3C); reduction in cytokine expression
after GO treatment may, therefore, indicate the involvement of
the innate immune system in regulating the effects of GO.70
More in-depth work is warranted to assess this possibility.
GO SHEETS ACCUMULATE PREFERENTIALLY IN
MARGINAL ZONE MACROPHAGES AFTER I.V.
ADMINISTRATION, BUT PROGRESSIVELY DISAPPEAR
FROM THE SPLEEN OVER NINE MONTHS
Following the determination of the impact of GO on mouse
spleen, we analyzed the sub-splenic biodistribution of the
material to reveal its long-term fate within this organ. For this
experiment, we used 7.5mg/kg of GO, rather than themaximum
10 mg/kg dose used in the above experiments. This selection
was based on observations that 10 mg/kg could induce
moderate but potentially significant modifications of the
immunological function of the spleen (Figure 3D); increase
cell apoptosis, despite being within a physiological range for
mouse spleen50,51 (Figure S5); and our previous observations27
of uncharacteristic mouse growth curves at this dose after one
month. All observations suggested that 10 mg/kg might be the
LOAEL dose in mice for this material over the long term.
Therefore, we selected a lower dose (i.e., 7.5 mg/kg) to reduce
the long-term risk to the animals’ health. This was important, as
we intended to study biodegradation over nine months, while
not compromising our ability to detect and track the fate of GO
during this long period. In agreement with this approach, no
impact on the growth curve of the GO-injected mice was
observed compared with the vehicle (Dex 5%) control-injected
mice (Figure S7) over the nine-month period.
Using confocal Raman mapping to track the injected GO
sheets in spleen sections, it was confirmed without ambiguity
that the observed brown material in the splenic marginal zone
had typical Raman spectroscopic fingerprints of GO (Figure 4A,
day 1). Previous literature studies have reported similar
accumulation in this region for other engineered nanoparticles,
including lipid-based nanoparticles10,78 and CNT.40,79 In the
spleen, the marginal zone is densely populated with various
strategically located phagocytic cells.10 The next step was,
therefore, to determine the precise identity of the specific cells
within the splenic marginal zone that sequestered GO. Using
immunofluorescence in correlation with conventional (point-
and-shoot) Raman spectroscopy in spleen sections, we found
that GO was sequestered primarily within a subset of splenic
macrophages. These were shown to be the marginal zone
macrophages (MZM), which stained positive for the ERTR-9
antigen,10 and were shown to contain GO by Raman analysis
(Figure 4B). Preferential uptake of GO by MZMs was further
confirmed using fluorescence-activated cell sorting (FACS)
followed by conventional Raman spectroscopy on isolated
splenocyte subpopulations (Figure 4C and Figure S8).
Within the spleen, MZMsmake up a small fraction of the total
splenocytes and are situated throughout the middle and outer
portion of the marginal zone.80 In these regions of the spleen,
blood, previously flowing under high pressure due to the
restrictive diameter of the terminal arterioles, emerges from the
white pulp and into the sinuses of the marginal zone.13 Due to
the open nature of this region, there is a lack of resistance, which
causes the blood to experience a dramatic deceleration in flow
velocity, resulting in a local decrease in blood pressure.10,13
Highly phagocytic MZMs take this opportunity to remove
unwanted particulates, including cellular debris and exogenous
particulates from the blood.10,13 We infer that GO sheets
circulating in the blood may have in the same way been taken up
by the MZMs, which have been repeatedly shown to internalize
engineered nanoparticles, including liposomes,10,11 polystyrene
microspheres,10 or CNTs,40 after i.v. administration.
We then attempted to probe the fate of the GO accumulated
in the marginal zone over time (from day 1 to day 270 after
administration, Figure 4A and B). Comparing spleen sections
from GO-injected mice analyzed at the different time points, we
observed a clear decrease in the abundance of detectable GO
and a corresponding loss in the GO Raman spectral integrity
from day 1 to day 270. Results from confocal Raman mapping of
spleen sections (Figure 4A) agreed with that of conventional
(point and shoot) Raman spectroscopy on individual
splenocytes (Figure 4B). In both cases, while the Raman
signature of GO was easy to identify at 24 h, the same signature
could hardly be detected at the later time points. The greatest
loss in GO-positive cells was observed during the first month
after administration (between day 1 and day 30), but it
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continued to decrease over the remaining course of the
experiment (Figure 4C).
Observation of loss of GO Raman signature may on one hand
be due to biodegradation of the material, leaving only a trace
amount of GO crystalline regions that were below the limit of
detection of Raman spectroscopy.81 On the other hand, it could
be explained by the elimination of the material. Indeed, it has
been previously shown that nanomaterials traveling through
blood can be noncovalently attached to RBCs.82 If this was the
case for GO, the sheets would be held in the RBC reservoir of the
Figure 5. Splenic biodegradation of GO over nine months following i.v. administration at a dose of 7.5 mg/kg. (a) (i) Splenic sections of mice
that were stained with H & E; scale bars represent 50 μm. Inset images show the presence of GOmaterial in the vicinity of cells of the marginal
zone; scale bars represent 10 μm. (ii) Average Raman spectra of GOpresent in physically homogenized spleen tissue at different time points, n =
10 ROI × 3 mice. (iii) TEM micrographs of GO sequestered within the vesicular compartments of marginal zone splenocytes over time; scale
bars represent 1 μm. The inset shows a magnification of the GO material at the respective time points; scale bars represent 500 nm. (iv)
Representative electron diffraction pattern line profiles of GO at different time points postadministration, with the respective diffractograms
inset; scale bars represent 10 1/nm. (b) Average number of dark areas present in the splenic marginal zone at each time point (n = 5 ROI × 3
mice) (*p < 0.05).(c) Evolution of the Raman I(D)/I(G) ratio over ninemonths (n = 10ROI× 3mice). Statistical significances for graphs B and
C are given in Tables S3 and S4, respectively.
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spleen andwould exit the organ carried by healthy RBCs without
being captured by phagocytic cells. However, this hypothesis
would not fit with the biodistribution pattern observed herein,
since the majority of RBCs within the spleen are present in the
red pulp13 and not in the marginal zone where GO appeared to
accumulate (Figure 3D). Our previous studies9,27 have also
shown that a large portion of administrated GO sheets are
excreted via the urinary tract (without causing damage to the
kidneys) soon after i.v. administration; this would not be
possible if large amounts of GO were bound to RBCs. This
suggests that GO sheets are more likely relatively free and not
carried by RBCs when circulating in the blood, leading to their
capture by MZMs when reaching the spleen.
Another possibility that would explain an over-time
elimination would be GO sheets inducing significant tissue
damage upon accumulation, which in turn would cause release
of splenic content, including iron (hemosiderin)83 and the
captured GO. However, our results showed no detectable
damage to the spleen (or decrease of hemosiderin) for up to one
month (Figures 2 and 3), when the greatest loss of GO signal
was observed. Similarly, no significant differences in the number
of apoptotic cells were found in the spleen of GO-injected mice
even after nine months (Figure 4D), although there was an
initial slight but statistically insignificant increase at day 1.
However, the extent of cell death was within the norm expected
for spleen tissue.50,51 In addition, on examining the TUNEL-
staining images, it is apparent that apoptosis was not
predominant in the marginal zone (Figure S9), where the
densest accumulation of GO was observed, at any time point.
Without completely negating the possibility of concomitant
elimination of the material via mechanisms that would require
further investigation, the absence of compelling evidence to
support elimination of the material leads us to conclude that
biodegradative processes were the more likely leading cause for
the loss of GO Raman signature in spleen sections. This
conclusion is supported by several studies showing that thin and
well-dispersed GO sheets, similar to those used in the present
study, are more likely to undergo biodegradation compared with
thicker and aggregated GO sheets in the presence of oxidative
enzymes.17,18 In particular, myeloperoxidase, an enzyme
typically produced by granulocytes and macrophages, including
MZMs, was shown to be unable to degrade highly aggregated
GO, but efficiently catalyzed degradation of well-dispersed GO
materials,17 such as those used herein. Such studies emphasize
the key role of the hydrophilicity, negative surface charge, and
colloidal stability of aqueously dispersed GO in relation to
biodegradation. In addition to this, the spleen has been
previously shown to have a stronger capacity to biodegrade
GBMs (especially GO-like, carboxylated graphene)6 than other
components of the MPS such as the lungs and liver.6,42
GO SHEETS BIODEGRADE IN THE MARGINAL ZONE
MACROPHAGES OVER NINE MONTHS
To further characterize the progressive in vivo biodegradation of
GO over nine months, we looked in more detail at the spleen
marginal zone cells in which GO sheets accumulate preferen-
tially. First, using H & E staining, we found evidence of the
consistent presence of slightly darkened regions within the
marginal zones of the spleen, at all tested time points (Figure 5A-
i). This agreed with the data presented in Figures 2−4, in which
dark regions were observed across the whole spleen. However,
these dark regions were present not only in GO-injected mice
(Figure 5A-i) but also in the Dex 5%-administered mice, albeit
more sparingly (Figure S10). The number of dark regions was,
therefore, quantified (Figure 5B) and revealed a clear association
between the higher number of dark regions in the marginal zone
and GO administration, compared with vehicle controls.
Importantly and consistent with the idea of progressive
degradation of GO, the number of marginal zone dark regions
in GO-treated mice decreased over time (more sharply during
the first 30 days), reaching values similar to those found in Dex
5%-treated mice by day 270 (Figure 5B).
To further confirm that progressive degradation of GO
entrapped in the spleen was taking place in GO-injected animals,
conventional Raman spectroscopy was used to detect the typical
Raman fingerprints of GO in physically homogenized spleen
tissue of mice injected with GO at different time points and for
up to nine month after administration. This allowed us to probe
GO biodegradation at the whole organ level, to reveal the full
extent of degradation for all the GO sheets entrapped in the
spleen. In agreement with previous data (Figure 4), we found
that the intensity of the Raman signature of GO dramatically
decreased over time (Figure 5A-ii). By nine months, the GO
Raman signature was barely recognizable, lacking all typical
spectral features of GO crystals. For reference, the complete
series of averaged spectra (n = 30) over the nine month study is
provided in Figure S11.
Going further in the analysis of the collected Raman spectra,
we extracted the peak intensity for the characteristic D vs G
bands of GBMs (D band at ∼1350 cm−1; G band at ∼1580
cm−1) and calculated the I(D)/I(G) intensity ratio for each time
point (Figure 5C). The data revealed that over nine months the
GO Raman signature in the spleen followed the expected three-
stage classification of disorder for graphitic carbon crystals.84
This theory is known as the amorphous trajectory of carbon and
describes the transformation of sp2-hybridized carbon structures
into amainly tetrahedral sp3 amorphous carbon phase.84 Prior to
injection, the GO material displayed a prominent D peak
(Figure 1), which is due to the breathing modes of sp2-
hybridized carbon bonds present in the structure’s hexagonal
rings. In order for the D peak to be visualized, charge carriers
must be inelastically scattered by a phonon and then undergo a
second elastic scattering by a defect within the material.85 The
presence of such a heightened D peak indicated, therefore, that
prior to injection theGO sheets were significantly defective from
a crystal point of view. This is expected considering the
conditions of the modified Hummers’ method used to oxidize
and exfoliate graphite to form GO.28,34,86 From day 1 to day 7
after administration, the I(D)/I(G) ratio of GO in the spleen
began to rise (Figure 5C), indicating that the degree of defects
within the material had increased, as expected per the first stage
of the amorphous trajectory of carbon and in correlation with
predictions of the Tuinstra−Koenin (TK) equation.87 The TK
equation relates the size of sp2-hybridized crystal domains within
graphitic materials as they become increasingly defective. The
equation predicts that as the size of the sp2-hybridized crystal
domain decreases, the I(D)/I(G) ratio will increase until a
minimum crystal domain size is reached. After this point, the
I(D)/I(G) is expected to decrease as the spectral peaks are
gradually attenuated and the spectra are such that the
assumptions of the TK equation no longer apply.84
The rise in the I(D)/I(G) ratio continued at a slow pace for
another week after injection (from day 7 to 14; Figure 5C). This
slow pattern can be explained by the presence of oxidized debris,
physisorbed to the surface of GO sheets. Such debris may have
degraded first, thereby offering protection to the underlying GO
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sheet, hence slowing the initial biodegradative process. The
presence of oxidized debris may be alluded to by the XPS O/C
atomic ratio (O/C = 0.5) measured in the GOmaterial, prior to
injection in animals. A previous study88 showed that GO,
prepared through a modified Hummers’method, often contains
significant quantities of physisorbed oxidized debris. These
debris consist mainly of highly oxidized nanometer-sized
polyaromatic molecules; their presence on GO sheets can lead
to high O/C ratios of around 0.4 or above. When such GO
materials are subjected to base washing, shown to remove these
physisorbed oxidized debris, significant reductions in the XPS-
derived O/C ratio to values of approximately 0.3 or below are
observed.88 This is due to the lower abundance of oxygen in the
sample following the removal of the oxidized debris by the base
washing. The protective effect of these oxidized debris may also
be enhanced by the in vivo-derived protein corona, which is
expected to form around any nanomaterial on contact with
biological fluids such as blood.
After day 14, the I(D)/I(G) ratio was observed to decrease
(in particular between day 14 and 30; Figure 5C), as expected as
part of the second stage of the amorphous trajectory of carbon. It
can be explained by the increasing presence of defects within the
2D structure of GO sheets, which eventually results in the
presence of significant amounts of amorphous carbon structures,
to such an extent that the assumptions of the TK equation no
longer apply.84,89 This inference is supported by studies in which
ion beams of increasing energies were directed at graphene
sheets. In these cases, the ions caused knock-on damage,
resulting in defects within the graphene sheets and consequent
alterations in the Raman spectral features over time,85 which
followed a similar pattern to what we observed herein for the
spleen-bound GO. The results of these ion-beam studies were
also discussed relative to the amorphous trajectory of carbon and
predictions of the TK equation.85 Several enzyme- and cell-
based studies investigating the biodegradation of GBMs also
displayed a similar pattern of Raman I(D)/I(G) ratio changes,
albeit under much shorter time frames.18,90
The presence of an increasing amount of defects and disorder
within the spleen-bound GO may also explain the increasingly
difficult-to-detect GO Raman signals beyond 24 h (as observed
in both conventional Raman spectroscopy (1 μm2 spot size;
Figure 4B, Figure 5A-ii) and confocal Raman mapping (mm2
wide tissue section area; Figure 4A)). Indeed, as time
progressed, attenuation of the two characteristic Raman
scattering peaks continued to occur, with subsequent decreases
in the I(D)/I(G) ratio (Figure 5C) until both peaks were hardly
detectable. By day 270, attenuation of both D and G bands was
consistent across samples with limited exceptions, indicating
that the crystalline structure of the accumulated material had
been largely lost (Figure 5A-ii).
We finally wanted to confirm visually that biodegradation of
GOwas occurring within the splenocytes and not extracellularly.
BF-TEM was used to image GO directly within the ultra-
structure of tissue-fixed cells. An acceleration voltage of 80 kV
was used, in order to reduce knock-on damage.91 Cell-entrapped
GO appeared to lose its characteristic appearance and become
increasingly defective over time (Figures 5A-iii and S12). This
was further validated by the evolution of the electron diffraction
patterns of intracellularly entrapped GO, which became
increasingly difficult to acquire (Figures 5A-iv and S13). At
day 1, it was relatively easy to locate intracellular GO structures
and acquire hexagonal diffraction patterns characteristic of GO
within cellular compartments (Figure 5A-iii and A-iv). However,
at longer time points, there was an overall decrease in the
abundance of material as well as the intensity measured for the
diffraction peaks associated with GO. This was attributed to a
progressive attenuation of the crystallinity of the GO to a more
amorphous structure due to biodegradation,17 as discussed
above and supported by the Raman results (Figures 5C and
S11). In further support of these findings, evidence of the
formation of holes within the planar structure of GO sheets was
identified at day 30 (Figure S14). These formations were not
apparent prior to injection or at early time points, i.e., before day
30, and could not be attributed to electron beam damage during
image acquisition. Beyond 30 days, cell-entrapped GO sheets
appeared too damaged to allow TEM imaging of further
degradation (i.e., more advanced holey formation) of the planar
structure. These observations and their time line may suggest a
structural biodegradation-related GO transition state, whereby
defects accumulate within the material and then erode away,
resulting initially in the creation of large holes within the GO
sheets and ultimately the complete loss of their planar structure.
Importantly, the structural changes in GO planes observed in
spleen sections could not be found in GO sheets incubated at 37
°C in the dark for nine months (i.e., material not injected in
animals; Figures S15 and S16), indicating that elements of the
spleen biologicalmilieu are likely responsible for these structural
changes.
Similar results have been documented several times in vitro
when sp2-hybridized carbon nanomaterials, including GBMs,
were exposed to oxidizing chemicals,19 peroxidase family
enzymes,17,18,23 and other enzymes such as cellular nicotinamide
adenine dinucleotide phosphate-oxidase (NADPH oxidase) or
induced nitrogen oxide synthase (iNOS).92 In terms of a
possible mechanism by which the GO sheets were being
biodegraded intracellularly, based on the extensive work
concerning CNT degradation in macrophages,93 it can be
envisioned that following phagocytosis in MZMs membrane-
bound NADPH oxidase was activated and catalyzed the
production of superoxide. Superoxide dismutase could then
convert the superoxide into hydrogen peroxide, which could
react with free radical nitric oxide to generate reactive
peroxynitrite. Peroxidase enzymes such as myeloperoxidase
(MPO) may also have a role in catalyzing production of
hypochlorite from peroxide and chloride ions, even though
macrophages, including MZMs, contain lower levels of MPO
than other immune cells such as neutrophils.94 Another
possibility is that Fe ions, present within macrophages,94
catalyzed the breakdown of peroxide to hydroxyl radicals. As a
result of these different processes, free radicals and reactive
species, including peroxynitrite, hypochlorite, and hydroxyl
radicals, could then attack reactive sites such as epoxide groups
present on the planes of GO sheets, resulting in hole formation
(as observed herein via TEM) and the eventual breakdown of
the whole graphitic lattice. Further research is, however,
warranted to confirm which molecular mechanism(s) is(are)
leading to biodegradation of GO in the mouse spleen.
An interesting and related question is the nature of the
resulting molecular byproducts of biodegradation and whether
they could be eliminated or not. Although we have not
determined the molecular identity or fate of these in vivo
generated degradation products, our study reveals that their
likely production and presence did not obviously jeopardize the
splenic health or growth curve of mice. Similarly, and in support
of our findings, previous studies have reported that the in vivo
administration of carbon nanomaterial biodegradation by-
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products, generated in vitro, lack toxic consequences for animal
subjects.95,96 However, further studies would help determine the
exact cellular mechanisms that catalyze the observed biode-
gradation of GO, as well as the precise molecular identity and
fate of the resulting degradation byproducts, for the latter, using
GO synthesized from 13C-labeled graphite for instance.
Besides the Raman, TEM, and electron diffraction properties
of GBMs probed herein, the materials’ photothermal properties
could also be exploited in future studies to similarly reveal
biodegradation; this would particularly be relevant to reduced
GO.97,98 Such a concept was previously applied to function-
alized CNTs in 2D microglial cell cultures.99 In this study,
photothermal imaging was used to track the fate of CNTs over
time, revealing their progressive disappearance from the
phagocytic cells. The same technique could, therefore, be
applied to quantitatively determine the dynamics of biode-
gradation of GBMs in biological systems.
In order to obtain more quantitative results regarding
biodegradation, as most of the techniques used herein were at
best only providing semiquantitative assessment, the use of
simpler biological models, such as in vitro 3D cell culturemodels,
should be explored. In these models, the applied/administrated
dose, the delivered dose, and the cellular dose of nanomaterials
may be easier to determine. Indeed, 3D cell culture models
represent a convenient midway point between 2D cell culture
models (which does not replicate adequately cell−cell and cell−
matrix interactions or the complex diffusion/transport processes
seen in 3D tissues)100,101 and true in vivo animal models.
Previous reports have demonstrated significant differences in the
interaction of nanomaterials with 2D cell cultures compared
with 3D cell cultures.100 This highlights the benefit of the latter
as a more predictive and representative biological model,
particularly when quantitatively determining critical doses of
administered materials, and the dynamics of material degrada-
tion in cells, as recently reported for biosynthesized magnetic
iron nanoparticles.102
CONCLUSIONS
We have provided evidence that following i.v. administration the
small proportion of GO sheets that were not initially excreted
but accumulated in the spleen did not induce histopathologic
damage. Importantly, we report the maintenance of the
functional (both hematological and immunological) integrity
of the spleen at doses as high as 10 mg/kg, although at the
highest dose administered slight immunological variations were
observed. Using confocal Raman mapping, as well as
immunohistochemistry and conventional Raman spectroscopy
in combination, to map the splenic distribution of GO, we
identified that a subpopulation of splenic macrophages, known
as the marginal zone macrophages, were the predominant cells
responsible for bioaccumulating the material. Finally, using an
array of techniques including Raman spectroscopy and TEM
coupled with electron diffraction, we tracked the fate of the
bioaccumulated GO over nine months and provide compelling
evidence, down to the ultrastructural level, to suggest the in vivo
biodegradation of GO to such an extent that the material lost its
detectable graphitic crystalline structure. This further suggests
that the initial accumulation of GO in the spleen was a transient
event. This important result supports the development of
thoroughly characterizedGO sheets for biomedical technologies
and is highly encouraging especially for systemic drug delivery
purposes, where the biocompatibility and biodegradability of
nanocarriers are a key advantage.103
EXPERIMENTAL SECTION
Graphene Oxide Preparation. The oxidation of graphite was
based on a modified Hummers’ method.86 Briefly, a mixture of 0.8 g of
flake graphite (Graflake 9580, Brazil) and 0.4 g of sodium nitrate
(NaNO3) was maintained at approximately 0 °C using an ice bath.
Then 18.4 mL of 96% sulfuric acid (H2SO4) was added to the mixture
while stirring, followed by the gentle addition of 2.4 g of potassium
permanganate (KMnO4). The mixture was taken from the ice bath.
After 30 min, the mixture increased in viscosity and resulted in the
formation of a dark-colored paste. A volume of 37 mL of Milli-Q H2O
was added. An increase in temperature to 80 °C was observed, and this
continued until 98 °C. The temperature was maintained at 98 °C for 30
min. After this duration, the mixture was diluted with a volume of 112
mL of warm Milli-Q H2O. A 12 mL aliquot of 30% H2O2 was added
subsequently. The suspension was centrifuged and pelleted repeatedly
at 7690g for 20 min; the supernatant was then removed and replaced
with Milli-Q H2O. This process was repeated until the acidic pH of the
supernatant was neutralized (pH 7, 20 °C) and a viscous orange/brown
gel layer of single-to-few-layer GO appeared on top of the graphite
oxidation byproducts. This gel-like layer was carefully extracted with
warm water to yield a dispersion of GO. A known volume of this
aqueously dispersed material was freeze-dried, and the dry material
weighed. This allowed the concentration of the extracted GO material
to be determined. The concentration of thematerial was found to be 2.4
mg/mL. The aqueously dispersed GO was then subjected to
ultrasonication for 5 min (VWR, 80W) to prepare the desired small
sheet size GO. The internal batch reference of GO used in the present
study is GO (f1s). Samples were characterized via AFM, TEM, selected
area electron diffraction (SAED), ATR FT-IR, TGA, XPS, UV−vis, and
fluorescence spectroscopy to confirm successful synthesis of single to
few layer small GO sheets.
Atomic Force Microscopy. Sample preparation was completed on
freshly cleaved mica, treated with 40 μL of poly-L-lysine (Sigma-
Aldrich, UK). The poly-L-lysine was used to present a positively charged
surface that would allow the adhesion of GO. Aliquots (10 μL) of GO
(100 μg/mL) were transferred onto the mica-poly-L-lysine surface and
left to adsorb for 2 min. Unbound structures were removed by gentle
rinsing with 2mL ofMilli-QH2O and left to dry at room temperature. A
multimode atomic force microscope (Bruker, UK) was applied in
tapping mode, in order to avoid damaging the samples, for height (trace
and retrace) and amplitude measurements. Measurements were
performed using an Otespa tapping mode tip (Bruker, UK). The
following parameters were employed: scan rate, 1 Hz; lines per scan,
512; integral gain, 1; proportional gain, 5; amplitude set point, 150 mV
(maintained approximately constant between all measurements). Scans
were taken at 50, 20, 10, 5, and 2 μm (aspect ratio 1:1). Postimage
processing was completed using the BrukerNanoscope Analysis version
1.4 software (Bruker, UK) and included section analysis for measuring
the cross-sectional height of samples.
Transmission Electron Microscopy for Material Character-
ization. A 20 μL aliquot of sample (200 μg/mL) was placed on a
carbon-coated copper grid (CF400-Cu) (Electron Microscopy
Services, UK) and left to adsorb for 2 min. Filter paper (Merk-
Millipore, UK) was used to gently remove the excess dispersedmaterial.
Then samples were observed with a FEI Tecnai 12 BioTWIN
microscope (FEI, NL) at an acceleration voltage of 100 kV. Images
were taken with a Gatan Orius SC1000 CCD camera (Gatan, UK). For
SAED of GO sheets, material samples was prepared as described above,
however, on Quantifoil S 7/2 copper grids (Electron Microscopy
Services, USA). SAED patterns were acquired on a FEI Talos 200X
(FEI, Eindhoven, NL), operating at 80 kV and using electron dose rates
ranging between 45 and 84 e−·A−1 s−1. This microscope was equipped
with a FEI Ceta CMOS camera. Patterns were acquired from 0.5 μm2
areas, corresponding to the 40 μm selected-area aperture. An
acquisition time of 1 s was used.
Raman Spectroscopy for Material Characterization. Samples
were prepared for analysis by drop casting 20 μL of GO (100 μg/mL)
dispersion onto a glass slide. Samples were left to dry for at least 2 h at
37 °C. Spectra were collected using a DXR Raman microscope
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(Thermo Fisher Scientific, UK) using a λ = 633 nm laser. Spectra were
considered between 250 and 3500 cm−1, enabling the visualization of
the D and G scatter bands. Prior to the measurements, the Raman
system was energy calibrated to a polystyrene reference material. The
calibrated instrument had an energy resolution of 2.5 cm−1. Spectra
were collected at a laser power of 0.4 mW with a magnification lens of
50× (numerical aperture: 0.75) with a 25 s exposure time and averaged
over five locations. Raman spectra were corrected for tissue
autofluorescence using a sixth-order polynomial baseline correction;
all spectra were normalized to the G peak for I(D)/I(G) calculation
using Origin Pro 8.5.1. software (Origin Lab, USA).
Attenuated Total Reflection Fourier Transform Infrared
Spectroscopy. A drop of GO dispersion was placed into a Tensor
27 FTIR machine (Bruker, UK) and dried for 5 min at 60 °C until a
powder remained. Spectroscopic analysis was carried out between 750
and 4000 cm−1. Data processing was completed using OriginPro 8.5.1.
software (Origin Lab, USA).
Thermogravimetric Analysis. Lyophilized GO (2 mg) was
weighed into a ceramic crucible set at 25 °C in a TGA 400
thermogravimetric analyzer (PerkinElmer, UK). Samples were initially
held at 100 °C for 5 min to reduce the presence of residual water. The
temperature was then increased at a rate of 10 °C per minute from 25 to
995 °C, with a nitrogen flow of 20 mL/min. Measurements were
considered between 100 and 800 °C to avoid water interference. Data
processing was completed using OriginPro 8.5.1. software (Origin Lab,
USA).
X-ray Photoelectron Spectroscopy. The chemical composition
of the GO sheets was studied by XPS at the NEXUS facility (the UK’s
National EPSRCXPSUsers’ Service, hosted by nanoLAB inNewcastle-
upon-Tyne). XPS spectra was recorded using a Thermo Theta Probe
XPS spectrometer with a monochromatic Al Kα source of 1486.68 eV.
The survey XPS spectra were acquired with a pass energy (PE) of 200
eV, a 1 eV step size, and a 50ms dwell time and averaged over five scans.
The etching step was 90 s. The high-resolution C 1s XPS spectra were
acquired with a PE of 40 eV, a step size of 0.1 eV, and a 100 ms dwell
time and averaged over 20 scans. Spectra from insulating samples were
charge-corrected by shifting all peaks to the adventitious carbon C 1s
spectral component, with the binding energy set to 284.6 eV. The
CasaXPS software was used to process the spectra acquired at NEXUS.
Processing steps included the C 1s XPS spectral deconvolution and
assignment of the different deconvoluted spectral components as per
the binding energies at which they arise. These assignments were made
in accordance with NIST’s XPS databases: π−π*: 290−290.2, O−C
O: 289.7−288.2 eV, CO: 288.1−287.4 eV, C−O: 286.8−286.2, C−
C and CC: 284.6 eV. The full width half-maximum of each
deconvoluted peak, other than that of the π−π*, was constrained to the
same extent, and a Shirley background was taken. The peak for C−C/
CC was of an asymmetric line shape, while the rest were of the
standard Gaussian−Lorentzian line shape.
UV/Visible Spectroscopy. The UV−vis absorbance spectra of GO
were measured by a Varian Cary win UV 50 Bio spectrophotometer
(Agilent Technologies, UK). The GO samples were diluted in water
from 7.5 to 20 μL/mL prior to measurement in a 1 mL glass cuvette
with a 1 cm path length. Dual-beam mode and baseline correction were
used throughout the measurements to scan the peak wavelength and
maximum absorbance between 200 and 600 nm.
Fluorescence Spectroscopy. Fluorescence emission spectra of
GOwere measured over a concentration range between 75 and 200 μg/
mL, using an LS-50B spectrofluorimeter (PerkinElmer, UK), with both
excitation and emission slits set at 20 nm. The excitation wavelength
used was 525 nm.
Animal Handling Procedures. Eight-week-old C57BL/6 mice
(18.1 ± 0.7 g) were obtained from Harlan (Oxfordshire, UK), allowed
to acclimatize for 1 week, and maintained under a 12 h light−dark cycle
at a steady temperature and humidity. Mice were allowed access to food
and water ad libitum for the duration of the investigation. All
experiments were conducted in accordance with the UK Home Office
Code of Practice (1989) for the housing and care of animals in scientific
procedures in accordance with prior approval from the UK Home
Office (Project License Number: P6C826A12). For short-term splenic
function and structural studies, mice (n = 3) were intravenously
administered with GO (2.5, 5, and 10 mg/kg) or Dex 5% (negative
control) and were culled for the different experiments after 24 h and 1
month. LPS (E. coli O127:B8, L4516-1MG; Sigma-Aldrich, UK) (5
mg/kg) at 24 h was used as the positive control. These mice were
maintained for only 24 h, since the mice showed symptoms of distress
and were therefore culled at this time point. LPS is known to illicit
inflammatory responses following injection and is commonly used as a
positive control in this respect. Relevant to our study, LPS can induce
increased levels of red blood cell deformity, pro-inflammatory
cytokines, and apoptosis;41,62 this is expected to result in alterations
to both structure and function of the spleen. Administration of LPS as a
positive control, therefore, allowed us to compare and gauge the
potential toxicological effects of GO on spleen structure and function.
For longer term degradation studies, mice (n = 3) were administered
with either 7.5 mg/kg or Dex 5% (negative control). The mass
concentrations of GO in the injection was 0.75 mg/mL, corresponding
to 150 μg of GO per injection. Mice were then culled at different time
points (1, 7, 14, 30, 90, 180, and 270 days following the single
administration) via being subject to terminal anesthesia followed by
cervical dislocation. For all experiments, mice were continuously
monitored and weighed every 4 days during the first month and weekly
thereafter.
Spleen Histopathological Analysis. Spleens of mice were fixed
with 4% paraformaldehyde and dehydrated through increasing
concentrations of alcohol (ethanol 50−100%) and embedded by
paraffin wax. Sections of 5 μm were cut on a microtome (Leica, UK),
stained with hematoxylin and eosin stain (H & E), coverslipped with
resinous mounting media, and allowed to dry for 48 h at 37 °C. Images
were collected using a 20× objective in a 3D Histech Panoramic 250
Flash slide scanner. Images were processed and analyzed using
Pannoramic Viewer (http://www.3dhistech.com/) and Fiji/ImageJ
software (version 1.5c; National Institutes of Health, USA). All three
mice were examined per condition.
Blood Smear Analysis. Blood was collected from mice via cardiac
puncture and immediately drawn into a capillary tube. One drop of
blood (approximately 4 mm in diameter) was placed on a clean slide
(near the end). The drop was spread by another glass slide placed at a
45° angle and pressed into the drop of blood, allowing it to spread via
capillary action. The slides were then fixed with cold methanol
(precooled to −20 °C) and allowed to dry at room temperature. The
samples were stained by H & E stain and imaged as described above.
Reticulocytes and abnormal and aged RBCs were considered as deviant
RBCs,52−56,104 and their percentage of the total RBCs was calculated.
More than 500 cells were counted for each mouse (n = 3 for each
group).
Perls’ Persian Blue Analysis of Spleen Sections. Paraffin-
embedded sections of spleens were sectioned at 5 μm and then
dehydrated as described above. The sections were stained with a freshly
prepared mixture of aqueous solutions of 20% hydrochloric acid and
10% potassium ferrocyanide trihydrate (Sigma-Aldrich, UK) at a
volume ratio of 1:1, followed by counter staining with nuclear fast red
0.2% aqueous solution. The slides were dehydrated through 95% and
100% ethanol solutions, respectively, with two consecutive changes for
each concentration. They were then coverslipped with resinous
mounting media and left to dry overnight. Images were collected as
described above. The percentage of blue pigmentation was analyzed by
Fiji/ImageJ software (version 1.5c; National Institutes of Health, USA).
This was obtained from three to four images from each mouse captured
at 20× after setting a threshold (n = 3 mice per group).
Spleen Single-Cell Suspension Preparation. Half spleens were
extracted from mice and placed immediately in RPMI 1640 media
(Sigma-Aldrich, UK) supplemented with 10% FBS (Gibco, Thermo
Fisher Scientific, UK) and 1% penicillin and streptomycin (Sigma-
Aldrich, UK). Single-cell suspensions were obtained by gently passing
the spleens through a 100 μm cell strainer (BD Falcon cell sieve). The
cell suspension was centrifuged at 400g for 5 min, and the supernatant
was discarded. The cells were resuspended in fresh media, and the
contaminating RBCs were removed by adding 3−4mL of red blood cell
lysis buffer (Roche, UK) and allowed to react at 4 °C for 5 min. The cell
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suspension was then centrifuged (400g for 5 min), and the cells were
pelleted while the supernatant was discarded. The cell pellet was then
resuspended and washed in fresh media twice. The splenocytes were
counted using a cytometer, aliquoted, and further processed as needed.
T-Lymphocyte Counts by Flow Cytometry. Splenocytes were
first preincubated with anti-CD16/32 antibodies at 2 μg/mL
(eBioscience, UK, ref #16-0161-85) for 20 min on ice, in order to
block nonspecific binding sites. The cells were washed (centrifuged at
400g for 5 min) and then labeled with the antibody mixture of anti-
CD4-PE at 0.25 μg/mL (eBioscience, UK, ref #12-0041-82) and anti-
CD8a at 0.25 μg/mL. PerCP-Cy5.5 (eBioscience, UK, ref #45-0081-
82) was further incubated with the cells on ice for another 20 min. Cells
were then washed and resuspended in buffer (1% sodium azide and 1%
FBS in 1× PBS) for acquisition. Flow cytometry analysis was carried out
using a BD FACSVerse flow cytometer (Becton Dickinson, Oxford,
UK). Single-color control samples were used to set compensation. PE
and PerCE-Cy5.5 fluorescence was detected with 574/26 nm and 690/
50 nm band-pass filters, respectively, after excitation with a 488 nm blue
laser. Data were analyzed and statistics were generated using the
FACSuite v1.6 software (Becton Dickinson, Oxford, UK).
Spleen Cytokine Gene Expression by RT-qPCR. An Aurum
Total RNAminikit (Biorad, UK) was used to extract the total RNA of 2
× 106 isolated splenocytes. The RNA concentration and quality were
analyzed using UV spectrophotometry (BioPhotometer, Eppendorf,
UK). cDNA synthesis was performed from 1 μg of RNA sample with an
iScript cDNA synthesis kit (Bio-Rad, UK) according to the
manufacturer’s instructions. The protocol for reverse transcription
was set as follows: 25 °C for 5 min, 42 °C for 30 min, 85 °C for 5 min,
and 4 °C for 5 min. A 2 μL amount of cDNA sample was used for each
real-time qPCR reaction performed with iQ SYBR Green Supermix
(Bio-Rad, UK). Experimental duplicates of each sample were run on a
CFX-96 real time system (Bio-Rad, UK) with the following protocol:
95 °C for 3min, one cycle; 95 °C for 10 s, 60 °C for 30 s: repeated for 40
cycles. Melt curve analysis was conducted at the end of the protocol to
confirm amplification of a single product. β-Actin was used as a
housekeeping gene, and gene expression levels were normalized to the
Dex 5%-injected control group. Primer sequences were as follows: β-
actin, Fwd 5′ GACCTCTATGCCAACACAGT 3′ and Rv 5′
AGTACTTGCGCTCAGGAGGA 3′; IL-6, Fwd 5′ ATGGATG-
CTACCAAACTGGA 3′ and Rv 5′ CCTCTTGGTTGAAGATATGA
3′; TNFα, Fwd 5′ CAGACCCTCACACTCAGATCATCT 3′ and Rv
5′ CCTCCACTTGGTGGTTTGCTA 3′; IL-1β, Fwd 5′ GGACAG-
AATATCAACCAACAAGTGATA 3′ and Rv 5′ GTGTGCC-
GTCTTTCATTACACAG 3′; IL-10, Fwd 5′ GGTTGCCAAGCC-
TTATCGGA 3′ and Rv 5′ ACCTGCTCCACTGCCTTGCT 3′;
TGF-β, Fwd 5′ GACCAGCCGCCGCCGCAGG 3′ and Rv 5′
AGGGCTGTCTGGAGTCCTC 3′.
Confocal RamanMapping of Tissue Sections.Mice were culled
and spleens were immediately extracted and washed in 1× phosphate
buffered saline (PBS) (Sigma-Aldrich, UK). One quarter of each
extracted spleen was immediately transversely immersed into the
optimal cutting temperature (O.C.T. compound, Tissue-Tek) media
and then snap-frozen in isopropanol (Sigma-Aldrich, UK) precooled to
liquid nitrogen temperatures. The spleens were cut into 5 μm thick
sections via cryomicrotomy (Leica, UK) and placed onto glass slides.
The tissue sections were then fixed using 300 μL of ice-cold methanol
(Sigma-Aldrich, UK) for 10min. The sections were subsequently gently
washed in 1× PBS twice in order to remove the O.C.T. compound.
Milli-Q water was used to remove any salt crystals from the PBS. The
sample was redoused with 300 μL of ice-coldmethanol and dried for 1 h
at 37 °C to dehydrate the sample. Raman scanning was completed on
regions of the spleen tissue including the red and white pulp regions.
Raman scanning was completed using a polystyrene calibrated DXRxi
Raman mapping system (Thermo Scientific, UK) using the following
conditions: λ = 633 nm, 1 mW, objective 50× (numerical aperture:
0.75), pixel size = 3 μm. The software was used to generate Raman
correlation maps based on the correlation of the acquired signal with
the spectra of the starting material shown in Figure 1C. The instrument
had an energy resolution of 2.5 cm−1. Dex 5%-treated animals were
analyzed in the same way to ensure no cross contamination as a quality
check.
Immunofluorescence with Raman Spectroscopy. Mice were
culled, and the spleens were immediately extracted and washed in 1×
PBS (Sigma-Aldrich, UK). One quarter of the spleen was immediately
transversely immersed into the O.C.T. compound and snap-frozen in
isopropanol (Sigma-Aldrich, UK) that was precooled to liquid-nitrogen
temperatures. The spleens were next sectioned into 5 μm sections via
cryomicrotomy, and the sections were collected onto glass slides
(VWR, UK). Afterward, the tissue sections were fixed using 300 μL of
ice-cold methanol (Sigma-Aldrich, UK) for 10 min. The methanol was
removed, and the fixed tissues were incubated in blocking buffer (1%
bovine serum albumin (fraction v, Sigma-Aldrich, UK), 0.1% Triton
X100 in 1× PBS) for 1 h in a humidification chamber. Tissue sections
were washed in a washing buffer that consisted of 0.1% Triton X100 in
1× PBS, three times for 5 min each. The washing buffer was removed,
and the tissue was incubated with the biotinylated Anti-SIGNRelated 1
antibody [ER-TR9] (#AB51819, Abcam, UK) diluted in blocking
buffer to 3.3 μg/mL for 2 h at room temperature in a humidification
chamber. The antibody solution was removed, and the tissue sections
were gently washed with the washing buffer three times for 5 min each.
The tissue sections were incubated with the revealing agent,
Fluorescein Avidin DCS (Vector Laboratories, UK), which was diluted
to 22 μg/mL with HEPES-buffered saline (pH 8.2, 20 °C), for 2 h in a
humidification chamber. The tissue was then washed with washing
buffer, and excess liquid was removed using a cotton bud. The tissue
sections were coverslipped with Prolong gold antifade including DAPI
(Thermo Fisher Scientific, UK). The sample was left in the dark at
room temperature for a 24 h period. Fluorescence microscopy was
completed, and the regions where ERTR-9 staining was detected were
marked on a customized grid. Controls consisting of either the revealing
agent (Fluorescein Avidin) alone without biotinylated antibody (to
ensure no signal was originating from the unspecific binding of the
revealing agent) or tissues from animals treated with dextrose 5% were
included in this experiment, in order to exclude false-positive readings.
The coverslips were later gently removed by incubating the slides in 1×
PBS overnight at room temperature. Following this treatment, the
coverslips could be removed via gravity; care was taken not to damage
the fixed tissue. The exposed tissues were gently washed with Milli-Q
water and left to dry at 37 °C for 1−2 h. Using the marked grids the
same regions identified by fluorescence microscopy were analyzed by a
“point-and-shoot” polystyrene calibrated DXR Raman microscope
(Thermo Fisher Scientific, UK) using a laser at λ = 633 nm, 0.4 mW,
50× (numerical aperture of 0.75) and an exposure time of 25 s and
averaged over three readings; the energy resolution of the instrument
was 2.5 cm−1. This allowed the colocalization of the Raman signature of
GO with the immunofluorescence signal of ERTR-9-positive marginal
zone macrophages. The spleens of at least three mice, with two or more
splenic sections, were imaged.
Fluorescence-Activated Cell Sorting with Raman Spectros-
copy.A single-cell suspension of splenocytes was obtained as described
above. The isolated cells were then stained with the relevant antibodies
mentioned below as per the manufacturer’s instructions. FACS was
then performed on live cells on a BD Influx cell sorter (BD Biosciences,
Oxford, UK). Fluorescently conjugated antibodies (Miltenyi Biotec
Limited, UK) were excited, and their emission was collected under the
following conditions: CD45-VioBlue, violet laser, band-pass 460/50;
F4/80-v770-PE, yellow-green laser, 750LP; CD11c-FITC, blue laser,
band-pass 530/40; CD209-PE, yellow-green laser, band-pass 585/29;
CD169b, red laser, band-pass 670/30. Cells were gated on an initial
scatter gate to exclude debris. Lymphocytes were identified as CD45+/
side scatter low and granulocytes were CD45+/side scatter high. F4/
80+/CD11c− macrophages were gated from the granulocyte gate and
CD11c+/F4/80− dendritic cells were gated from this population too.
The CD209+ and CD169b+ cells were identified as being F4/80−/
CD11c− and identified by plotting them against each other. Baseline
voltages were set using unlabeled cells, and positive populations were
identified using full minus one (FMO) controls. Cells were filtered
through a 50 μmmesh prior to being sorted through a 100 μmdiameter
nozzle at 20 PSI pressure, which generated a drop drive frequency of 38
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kHz. Sort side streams were optimized to enable five separate
populations to be collected simultaneously from each individual
sample. Up to 20 000 cells were collected depending on the frequency
of the cell subpopulation in the sample. The event rate was maintained
at 2000−3000 events per second to minimize aberrant droplet
formation and ensure a high degree of purity in the sorted cells. Cells
were collected into 1.5mL tubes containing 1× PBS and then deposited
onto glass slides via a Cytospin apparatus using a centrifuge set to 350g.
The cells were fixed onto the glass slide with a drop of ice cold
methanol. Once dry, the sample was analyzed via Raman microscopy
using a DXR Raman microscope (Thermo Fisher Scientific, UK)
calibrated to polystyrene with an energy resolution of 2.5 cm−1.
Measurements used a laser at λ = 633 nm, 0.4 mW, 50× (numerical
aperture of 0.75), and an exposure time of 25 s and averaged over three
readings. The percentage of scanned cells in which GO was detected
was determined at each time point, n = three mice × 20 cells. Cells
isolated from Dex 5%-treated mice were processed in the same way and
scanned to ensure there was no cross contamination of GO between
samples.
TUNEL Staining. Spleen sections were embedded in paraffin wax,
sectioned to 5 μm thickness on amicrotome (Leica, UK), and placed on
glass slides. The sections then underwent deparafinization via two
immersions in xylene for 5 min each, followed by washing in 100%
methanol for 5 min. The samples were subsequently rehydrated by
passing them through a series of decreasing concentrations of alcohol
concentrations (100%, 95%, 85%, 70%, 50%) for 3 min at each
concentration. The sections were further washed in 0.85% NaCl for 5
min. The rehydrated sections were fixed in 4% formaldehyde (ref
#28908; Thermo Fisher Scientific, UK) for 15 min. The remaining
formaldehyde was then removed by washing in PBS 1× (Sigma-Aldrich,
UK) twice for 5 min each. The excess PBS was removed gently with
filter paper, being careful to not touch the sections. The glass slides with
their fixed sections were then placed on a flat surface, and 10 μL of a 20
μg/mL proteinase-K solution was placed on each tissue section. The
slides were left with the proteinase K solution for an optimized time of 8
min. Proteinase K was removed by washing with PBS for 5 min. Then
the tissue was covered with 100 μL of equilibrium buffer and left to
equilibrate for 5min. The equilibrium buffer was removed, and 50 μL of
rTdT incubation buffer was added onto each slide and left for 60 min in
a humidification chamber at 37 °C. The slides were next immersed in
physiological saline (sodium chloride) 2× to terminate the reaction.
The slides were then washed in PBS 1× (Sigma, UK) twice for 5 min
and then washed twice in Milli-Q water for another 5 min each. The
slides were, thereafter, incubated in 4% Sudan black (in ethanol) for 10
min to eliminate RBC-derived fluorescence, followed by washing seven
times in PBS 1× (Sigma, UK) for 3 min each and three washes in Milli-
Q water for 3 min each. The slides were coverslipped with Prolong gold
antifade including DAPI (Thermo Fisher Scientific, UK) and left at
room temperature in the dark for 24 h. Images were collected using a
20× objective in a 3D Histech Panoramic 250 Flash slide scanner.
Images were processed and analyzed using Pannoramic Viewer (http://
www.3dhistech.com/) and Fiji/ImageJ software (version 1.5c; Na-
tional Institutes of Health, USA). Three mice were examined per
condition. A total of five images of 300 μm2 were analyzed per mouse.
The number of TUNEL-positive cells was blindly counted by three
independent investigators, and the counts of the three individuals were
averaged for each image.
Raman Spectroscopy on Homogenized Spleens. For each
time point analyzed, a quarter of the extracted and washed individual
murine spleens were homogenized mechanically onto a glass slide and
left to dry for 30−60 min at room temperature and pressure. This was
completed in order to assess the state of the overall GO content of the
spleen, instead of cell-specific content. Raman spectroscopy was
performed on the tissue homogenates using a polystyrene calibrated
DXR Raman microscope (Thermo Fisher Scientific, UK) using a λ =
633 nm laser a 50× objective lens (numerical aperture of 0.75) and a
laser power of 0.4 mW with an exposure time of 25 s. The energy
resolution was 2.5 cm−1. Raman scattering signals were acquired in at
least 10 different regions per mouse with three biological replicas.
Raman spectra were corrected for tissue autofluorescence using a sixth-
order polynomial baseline correction, and the ratio of intensity of the D
and G peaks, I(D)/I(G), was calculated and averaged for n = 10 spectra
for each of the three mice. We also scanned Dex 5%-treated animals in
the same way to ensure no cross contaminations as a quality check.
Histological Marginal Zone Analysis. For each time point in the
degradation study, a quarter of the spleen was fixed with 4%
paraformaldehyde and dehydrated through increasing concentrations
of ethanol (50−100%) and embedded in paraffin wax. Sections of 5 μm
thickness were cut and collected onto glass slides and then stained with
H & E stain. The stained sections were then coverslipped with resinous
mounting media and allowed to dry for 48 h at 37 °C. Images were
collected using a 20× objective and a 3D Histech Panoramic 250 Flash
slide scanner. Images were processed and analyzed to determine the
average number of dark regions in the splenic marginal zone (n = 5
marginal zones for each of the three mice) using Panoramic Viewer
(http://www.3dhistech.com/) and Fiji/ImageJ software (version 1.5c;
National Institutes of Health, USA).
TEM on Splenic Tissue Sections. For each time point analyzed, a
quarter of each of the extracted and washed murine spleens was fixed in
paraformaldehyde (4% (w/v))/glutaraldehyde (2.5% (w/v)) (Sigma-
Aldrich, UK) for 24 h. Following fixation, specimens were cut into 2−3
mm blocks using a sterile surgical blade. Each specimen was washed
several times with deionized water, submitted to a second fixation with
reduced osmium tetroxide (OsO4) (Agar Scientific, UK) for 90 min,
then rinsed with deionized water and dehydrated through a series of
concentration-graded ethanol (Thermo Fisher Scientific, UK)
solutions, 30%, 50%, 70%, 90%, and 100%. The specimens were
incubated at each concentration for 15 min; dilutions were made in
Milli-Q water. This was followed by the incubation of the specimen in
100% acetone (Thermo Fisher Scientific, UK) for 15 min. Each
specimen was infiltrated with increasing concentrations of polypropy-
lene TAAB 812 hard resin (TAAB Laboratories Ltd., UK) (25%, 50%,
75%, and 100%, using acetone as the diluent) for 12 h at each grade.
Next, specimens were left in 100% resin for a further 6 h at room
temperature. Specimens were, thereafter, orientated in the embedding
mold filled with fresh 100% resin, such that transversal sectioning of the
spleen sample would be possible. The resin (with the orientated
sample) was then cured at 60 °C for 48 h to allow resin polymerization.
TEM imaging was performed on ultrathin sections (approximately 40−
70 nm thickness) obtained using an Ultracut E ultramicrotome
(Reichert-Jung, Austria) and a diamond knife (Diatome 45°, Leica,
UK). Ultrathin sections were collected onto coatless 200-mesh thin
copper 3.05 mm grids (Electron Microscopy Services, USA) and
observed under a FEI Tecnai T-12 BioTWIN TEM (FEI, Eindhoven,
NL) equipped with an Orius CCD SC100 camera (Gatan, UK) at 100
kV. The use of this microscope and grids allowed efficient observation
of the whereabouts and tracking of the GO within tissue. We also
scanned Dex 5%-treated animals in the same way to ensure no cross
contamination as a quality check.
Electron Diffraction of GO in Tissue Sections. Tissues were
fixed and resin-embedded, and ultrathin sections were prepared for
TEM, as described above. In this experiment, the ultrathin sections
were collected onto Quantifoil S 7/2 copper grids (Electron
Microscopy Services, USA). TEM and SAED shown in Figures 5A-iv,
S13, and S14 were performed on a FEI Talos 200X (FEI, Eindhoven,
NL) operating at 80 kV and using electron dose rates ranging between
45 and 84 e−·A−1 s−1. TEM images and SAED patterns were acquired
using a FEI Ceta CMOS camera on an area of 3.14 × 10−2 and 0.5 μm2
corresponding to the selected-area apertures of 10 and 40 μm,
respectively. An acquisition time of 1 s was used for the collection of
TEM images and SAED patterns. However, for the acquisition of SAED
patterns with a 10 μm selected-area aperture, the acquisition time was
set to 8 s.
Statistical Analysis. All experimental data are represented as mean
± standard error (SE) or mean ± standard deviation (SD) as stated in
each section, with at least n = 3, 4. Statistical significance was
determined by the Kruskal−Wallis nonparametric test with Dunn’s
posthoc test or a Mann−Whitney U test for pairwise comparisons where
appropriate. For RT-qPCR data Levene’s test for homogeneity of
variances was performed, if it showed significance (p < 0.05); then
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Welch ANOVA and a Games-Howell’s posthoc test were performed.
SPSS software, version 22.0, was used to perform this analysis. In all
experiments, probability values of <0.05 were considered significant.
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McCaffrey, J.; Meńard-Moyon, C.; Rodrigues, A. F.; Bianco, A.; Haigh,
S.; Lennon, R.; Kostarelos, K. The Effects of Extensive Glomerular
Filtration of Thin Graphene Oxide Sheets On Kidney Physiology. ACS
Nano 2016, 10, 10753−10767.
(28) Rodrigues, A. F.; Newman, L.; Lozano, N.; Mukherjee, S. P.;
Fadeel, B.; Bussy, C.; Kostarelos, K. A Blueprint for the Synthesis and
Characterisation of Thin Graphene Oxide With Controlled Lateral
Dimensions for Biomedicine. 2D Mater. 2018, 5, No. 035020.
(29) Georgakilas, V.; Otyepka, M.; Bourlinos, A. B.; Chandra, V.; Kim,
N.; Kemp, K. C.; Hobza, P.; Zboril, R.; Kim, K. S. Functionalization of
Graphene: Covalent and Non-Covalent Approaches. Chem. Rev. 2012,
112, 6156−6214.
(30) Vacchi, I. A.; Spinato, C.; Raya, J.; Bianco, A.; Menard-Moyon, C.
Chemical Reactivity of Graphene Oxide Towards Amines Elucidated
By Solid-State NMR. Nanoscale 2016, 8, 13714−13721.
(31) Bianco, A.; Cheng, H.-M.; Enoki, T.; Gogotsi, Y.; Hurt, R. H.;
Koratkar, N.; Kyotani, T.; Monthioux, M.; Park, C. R.; Tascon, J. M. D.;
Zhang, J. All In the Graphene Family − A Recommended
Nomenclature for Two-Dimensional Carbon Materials. Carbon 2013,
65, 1−6.
(32) Ilium, L.; Davis, S. S.; Wilson, C. G.; Thomas, N. W.; Frier, M.;
Hardy, J. G. Blood Clearance and Organ Deposition of Intravenously
Administered Colloidal Particles. The Effects of Particle Size, Nature
and Shape. Int. J. Pharm. 1982, 12, 135−146.
(33) Bussy, C.; Ali-Boucetta, H.; Kostarelos, K. Safety Considerations
for Graphene: Lessons Learnt FromCarbonNanotubes.Acc. Chem. Res.
2013, 46, 692−701.
(34) Jasim, D.; Lozano, N.; Kostarelos, K. Synthesis of Few-Layered,
High-Purity Graphene Oxide Sheets From Different Graphite Sources
for Biology. 2D Mater. 2016, 3, No. 014006.
(35) Figueiredo, J. L.; Pereira, M. F. R.; Freitas, M. M. A.; Órfaõ, J. J.
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